274 related articles for article (PubMed ID: 31882676)
1. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.
Arenas A; Serrano C; Quiñones L; Harris P; Sandoval M; Lavanderos M; Sepúlveda R; Maquilón S; Echeverría A; Ríos C; Fuentes-López E; Rojas L; Jorquera A; Pizarro M; Camargo MC; Riquelme A
Sci Rep; 2019 Dec; 9(1):20070. PubMed ID: 31882676
[TBL] [Abstract][Full Text] [Related]
2. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
3. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
4. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis.
Chang YW; Ko WJ; Oh CH; Park YM; Oh SJ; Moon JR; Cho JH; Kim JW; Jang JY
Korean J Intern Med; 2019 Sep; 34(5):1022-1029. PubMed ID: 29898576
[TBL] [Abstract][Full Text] [Related]
5. Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Hwang JY; Kim C; Kwon YH; Lee JE; Jeon SW; Nam SY; Seo AN; Han MH; Park JH
Dig Dis; 2021; 39(5):451-461. PubMed ID: 33429397
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial.
Zhou L; Zhang J; Chen M; Hou X; Li Z; Song Z; He L; Lin S
Am J Gastroenterol; 2014 Apr; 109(4):535-41. PubMed ID: 24642580
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
[TBL] [Abstract][Full Text] [Related]
9. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Kutluk G; Tutar E; Bayrak A; Volkan B; Akyon Y; Celikel C; Ertem D
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1202-8. PubMed ID: 25171023
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial.
Ladrón-de-Guevara L; Bornstein-Quevedo L; González-Huezo S; Castañeda-Romero B; Costa FG; di Silvio-López M
Rev Gastroenterol Mex (Engl Ed); 2019; 84(3):274-283. PubMed ID: 30060902
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa.
Gonzalez-Hormazabal P; Musleh M; Escandar S; Valladares H; Lanzarini E; Castro VG; Jara L; Berger Z
BMC Gastroenterol; 2018 Jun; 18(1):91. PubMed ID: 29925321
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant
Kim JJE; Kocsmár I; Buzás GM; Szirtes I; Rusz O; Diczházi C; Szijártó A; Hritz I; Schaff Z; Kiss A; Kocsmár É; Lotz G
Pathol Oncol Res; 2021; 27():1609863. PubMed ID: 34267605
[TBL] [Abstract][Full Text] [Related]
15. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
[TBL] [Abstract][Full Text] [Related]
16. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study.
Yi DM; Yang TT; Chao SH; Li YX; Zhou YL; Zhang HH; Lan L; Zhang YW; Wang XM; Zhang YR; Li J; Ding SZ
Medicine (Baltimore); 2019 Feb; 98(6):e14408. PubMed ID: 30732192
[TBL] [Abstract][Full Text] [Related]
17. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R
Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044
[TBL] [Abstract][Full Text] [Related]
18. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides.
Kocsmár É; Buzás GM; Szirtes I; Kocsmár I; Kramer Z; Szijártó A; Fadgyas-Freyler P; Szénás K; Rugge M; Fassan M; Kiss A; Schaff Z; Röst G; Lotz G
Nat Commun; 2021 Apr; 12(1):2255. PubMed ID: 33859206
[TBL] [Abstract][Full Text] [Related]
19. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Leow AH; Azmi AN; Loke MF; Vadivelu J; Graham DY; Goh KL
J Dig Dis; 2018 Nov; 19(11):674-677. PubMed ID: 30307122
[TBL] [Abstract][Full Text] [Related]
20. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
